Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights
- RADR® A.I. platform surpasses 10 billion datapoints, significantly enhancing speed and scope of new drug development and expanding potential for biopharma collaborations - Drug candidate LP-184 granted Orphan Drug Designations by the FDA for the treatment of glioblastoma multiforme and pancreatic cancer - Preparing to launch multiple human clinical trials in the next several quarters for LP-300, LP-184 and LP-100 - $73.8 million of cash, cash equivalents and marketable securities as of September 30, 2021
To create an account please click on this link.
If you already have an account, please log in here.